1. ALLA AKTIER
  2. NYHETER
  3. ACARIX

Acarix

Nyheter Acarix Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces effective May 1, 2024, that the CADScor System CPT III 0716T code has been officially removed from the United Healthcare Medicare Advantage non-covered list. This important development marks the first step in removing barriers to widespread usage for patients covered by this plan.

"We are thrilled to announce that the CADScor System CPT III 0716T code has been removed from the non-covered list for United Healthcare Medicare Advantage," said Aamir Mahmood, President & CEO of Acarix. "This decision reflects a positive change in patient accessibility. By allowing payment for the test, United Healthcare Medicare Advantage is aligning with the healthcare industry's shift towards value-driven practices, emphasizing quality and efficiency. The CADScor System provides an accurate and non-invasive tool for risk stratification of coronary artery disease at the point of care, enabling clinicians to make decisions, leading to better outcomes and cost-effective care."

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List

Datum 2024-05-20, kl 10:40
Källa MFN
Bifogade filer
Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List